Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome.

Canakinumab Schnitzler syndrome autoinflammatory disorders immunohistochemical neutrophilic inflammation

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2023
Historique:
received: 21 09 2022
accepted: 22 02 2023
medline: 4 4 2023
entrez: 3 4 2023
pubmed: 4 4 2023
Statut: epublish

Résumé

Interleukin-1 (IL-1)-blocking therapies are effective in reducing disease severity and inflammation in Schnitzler syndrome. Here, we present a patient with Schnitzler syndrome treated successfully using canakinumab for over 10 years. Complete clinical response was associated with a decrease in dermal neutrophil number and expression of the pro-inflammatory cytokines IL-1β, IL-8, and IL-17 as assessed by immunohistochemical studies.

Identifiants

pubmed: 37007766
doi: 10.3389/fmed.2023.1050230
pmc: PMC10050468
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1050230

Informations de copyright

Copyright © 2023 Bossart, Seyed Jafari, Heidemeyer, Yan, Feldmeyer, Borradori and Yawalkar.

Déclaration de conflit d'intérêts

NY has served as a consultant for Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Curr Rheumatol Rep. 2017 Aug;19(8):46
pubmed: 28718061
Expert Rev Clin Immunol. 2010 Nov;6(6):831-41
pubmed: 20979548
Blood. 2003 Nov 15;102(10):3759-64
pubmed: 12881316
Arthritis Res Ther. 2015 Jul 22;17:187
pubmed: 26198339
Front Immunol. 2019 Mar 22;10:546
pubmed: 30967871
MAbs. 2010 Jan-Feb;2(1):3-13
pubmed: 20065636
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Br J Pharmacol. 2020 Aug;177(16):3635-3645
pubmed: 32441764
Acta Haematol. 2008;120(1):1-4
pubmed: 18612198
J Allergy Clin Immunol. 2020 Jun;145(6):1681-1686.e5
pubmed: 31940469
J Allergy Clin Immunol. 2015 Feb;135(2):561-4
pubmed: 25239704

Auteurs

Simon Bossart (S)

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

S Morteza Seyed Jafari (SM)

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Kristine Heidemeyer (K)

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Kexiang Yan (K)

Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.

Laurence Feldmeyer (L)

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Luca Borradori (L)

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Nikhil Yawalkar (N)

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Classifications MeSH